Sleep Disorders

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

The cofounder and chief scientist at Big Health and professor of sleep medicine at the University of Oxford discussed the recent findings of a study of Sleepio in poststroke rehabilitation and the role that cognitive behavioral therapy could play in that care process.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 13, 2022.

The digital cognitive behavioral therapy improved sleep for almost half of the study cohort and showed additional signs of improvement for depression and anxiety among individuals in rehabilitation for stroke.

Margaret Park, MD, and Russell Rosenberg, PhD, DABSM, provide clinical pearls and the future treatment landscape for the management of narcolepsy.v

Drs Margaret Park and Russell Rosenberg share considerations for the use of solriamfetol, lower-sodium oxybate, and pitolisant in narcolepsy for various patient populations.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 6, 2022.

DSP-0187, an orexin-2 receptor agonist, adds to Jazz’s portfolio of sleep disorder therapies, expanding it into a new medicine class. The molecule will be referred to as JZP441 by Jazz.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Key opinion leaders in sleep medicine discuss the pitolisant studies and their experience using the drug in clinical practice.

Margaret Park, MD, and Russell Rosenberg, PhD, DABSM, provide insight on novel FDA-approved treatment options and their impact on the narcolepsy treatment landscape.

A greater number of hypothalamic wake-promoting neurons were associated with a lower percentage of time in stage 2 of non-REM sleep and REM stages.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

Neurology News Network for the week ending April 30, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 29, 2022.

Pitolisant, an agent that originally received FDA-approval in 2019 to treat excessive daytime sleepiness in narcolepsy, will have efficacy and safety evaluated in a cohort of 200 patients with idiopathic hypersomnia.

Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.

Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.

Margaret Park, MD, leads the discussion on setting and managing patient expectations for treatment in narcolepsy.

Expert sleep specialists review the case of a 22-year-old man who is diagnosed with excessive daytime sleepiness and type 2 narcolepsy and his challenges with treatment.

Despite a low percentage of patients missing work time due to their condition, a higher percentage reported impairment while working, overall work impairment, and activity impairment.

Here's what is coming soon to NeurologyLive®.